Paul Hastings LLP advised Jasper Therapeutics on the deal. Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
Jasper Therapeutics’ $103.5 Million Public Offering
Scilex Holding’s $1.64 Billion Merger with Vickers Vantage Corp. I
Paul Hastings LLP advised Scilex Holding Company on the deal. Scilex Holding Company announced its agreement to merge with Vickers Vantage Corp. I (VCKA), a special purpose...